Marc S. Ernstoff MD

Contact Information:

Phone: (603) 650-5091

Fax: (603) 650-7791

Email: not given

Institution Affiliations:

Professor of Medicine (Hematology/Oncology)

Department of: MEDICINE

Section: Hematology/Oncology

Specialty: Hematology/Oncology

Joined Staff: 1991

Cancer Center Membership:

Genitourinary / Prostate Clinical Oncology Group

Immunology and Cancer Immunotherapy Research Program

Prostate/Geritourinary Clinical Trials

Melanoma Clinical Trials

Clinical Interests:

Melanoma

Prostate Cancer

Genitourinary Cancer

Board Certified:

Hematology/Oncology

Medical Oncology 1989

Internal Medicine 1981

Degree(s): MD

New York University School of Medicine, New York, NY 1978

Internship(s):

Residency:

Bronx Municipal Medical Center & The Hospital of the Albert Einstein College of Medicine, Bronx, NY, (Internal Medicine) 1978-81

Fellowship(s):

Yale University School of Medicine, New Haven, CT, (Medical Oncology) 1981-84

Biography:

Dr. Ernstoff received his BA in the history of art from Emory University in 1974 and his M.D. from New York University of Medicine in 1978. After completing internal medicine training at the Bronx Municipal Hospital Center and the Hospital of Albert Einstein College of Medicine, he continued his training in Medical Oncology at Yale University, where he stayed on faculty as an Assistant Professor of Medicine and Director of the Office of Clinical Research of the Yale Comprehensive Cancer Center until 1986. In 1986, Dr. Ernstoff joined the faculty at the University of Pittsburgh and the Pittsburgh Cancer Institute, where he was an Associate Professor of Medicine and Surgery, Director of the Hematology/Oncology Fellowship Program, and the Medical Director of Genitourinary Cancer Group until 1991 at which time he joined the faculty of the DHMC. Dr. Ernstoff is currently an oncologist in the field of GU and Melanoma.

Research Interests:

Dr. Ernstoff's laboratory has been involved with developing clinical use of cytokines in the treatment of metastatic renal cell carcinoma or melanoma. Correlative laboratory studies suggest that T cell mediated pathways may be triggered by the interferons causing tumor regression. Further studies exploiting this observation include trials employing tumor vaccines and sequential combination of cytokines. The development of tumor specific vaccines for the treatment of renal cell carcinoma and prostate cancer are currently being explored in the laboratory and clinic. Cytokine modulation of vaccine response is currently being explored using autologous renal cell carcinoma and interferon alpha combined with interferon gamma in patients with metastatic renal cell carcinoma. Preliminary studies suggest that cytolytic T cell pathways may be activated through this approach. In a related area, the laboratory is attempting to identify tumor-specific immunodominant peptides that exist on prostate carcinoma. Immunodominant peptides are identified using the Tsites program, which predicts for 8-15 amino acid sequences that bind to the major groove of the MHC molecule. To enhance peptide presentation to monocytes, immunodominant sequences are conjugated to a monoclonal antibody to the Fc-gamma RI receptor.

Grants:

2003-2008 : PI
NIH/NCI/Cancer and Leukemia Group B
Patients with breast cancer, leukemia, lymphoma, GI malignancies, GU cancer and other malignancies

2003-2004 : Co-PI
Hitchcock Foundation/Hitchcock Foundation Grant: Dendritic Cell Vaccine therapy in Melanoma

2003-2006 : PI
NIH (1 RO1 CA095648-01): Immunotherapy of Renal Cell Carcinoma

2005-2008 : Co-PI
Leukemia & Lymphoma Society: Lymphodepletion and Adoptive Immunotherapy for Transplanted Myeloma Patients

2005-2006 : Co-PI
Hitchcock Foundation Grant: Molecular Footprint of DC

2006-2008 : PI
NIH (1 R21 CA112761-01A1): Lymphodepletion for Melanoma Patients/ Score 135 (4.8 percentile) Pending

2006-2008 : Co-I
NIH (1 R21 CA121593A)/Determination of Clinical Feasibility of EPR Oximetry of Tumors/Score 134 (3.6 percentile) Pending

Selected Publications:

Waller EK and Ernstoff MS. Modulation of antitumor immune responses by hematopoietic cytokines. Cancer, 97 (7): 1797-1809, 2003.

Kirkwood JM, Ibrahim J, Ernstoff MS, Manola J, Sondak V and Rao U. A Pooled Analysis of Eastern Cooperative Group and Intergroup trials of Adjuvant High-Dose Interferon Alfa-2b for High-Risk Resected Cutaneous Melanoma. Clin Cancer Res, 10 (5): 1670-1677, 2004.

Schwaab T, Tretter C, Gibson J, Cole B, Schned A, Harris R, Wallen E, Fisher J, Waugh M, Truman D, Stempkowski L, Crosby N, Heaney J and Ernstoff MS. Immunological Effects of GM-CSF and Autologous Tumor Vaccine in Patients with Renal Cell Carinoma. J Urol, 171 (3): 1036-1042, 2004.

Titus-Ernstoff L, Perry A, Spencer S, Gibson J, Cole BF and Ernstoff MS. Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer, 116 (1): 144-149, 2005.

Crocenzi TS, Tretter CPG, Schwaab T, Schned AR, Heaney JA, Cole BF, Fisher JL and Ernstoff MS. Impaired Cytolytic Activity in Peripheral Blood T Cells from Renal Cell Carcinoma Patients. Clin Immunol, 117 (1): 6-11, 2005.

Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Dongsheng Z, Houghton A and Haluska FG. Phase II study of the g209-2M melanoma peptide vaccine and low dose interleukin-2 in advanced melanoma. J Immunother, (in press).

Schwaab T, Tretter CPG, Gibson JJ, Cole BF, Schned AR, Harris R, Fisher JL, Crosby N, Stempkowski LM, Heaney JA and Ernstoff MS. Tumor-related Immunity in Prostate Cancer Patients Treated with Human Recombinant Granulocyte Monocyte Colony Stimulating Factor (GM-CSF). The Prostate, (in press).

Mailing Address:
Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756